Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKainos Group Regulatory News (KNOS)

Share Price Information for Kainos Group (KNOS)

Share Price is delayed by 15 minutes
Get Live Data
771.50    3.00 (0.39%)
Bid:
770.00
Ask:
774.00
Spread: 4.00 (0.519%)
Market Cap: £889.50m
KNOS Live PriceLast checked at - London Stock Exchange

Intraday Kainos Group Share Chart

Kainos Acquires Formulate and Implexa

11 Nov 2019 07:01

RNS Number : 8720S
Kainos Group plc
11 November 2019
 

RNS REACH

11 November 2019

Kainos Group plc

 

("Kainos" or the "Company")

 

Kainos Acquires Formulate and Implexa

 

Kainos (LSE: KNOS), a leading UK-based provider of digital services and platforms, is pleased to announce today further investment into Adaptive Insights' UK and European markets through the acquisitions of Formulate (Adaptive) Limited ("Formulate"), and the Adaptive Insights arm of Implexa GmbH ("Implexa").

 

Formulate is a leading UK and European partner to Adaptive Insights: a financial and business planning software business which is part of Workday, Inc. Established in 2016 and headquartered in Worcestershire in the UK, Formulate is one of the leading European partners to Adaptive Insights. Formulate supports customers in implementing Adaptive Insight's software; building and refining forecasting solutions. Formulate's team of 16 combines both software and consulting capabilities, and provides its services to more than 100 customers across the UK and Europe.

 

Implexa is the only accredited Adaptive Insights partner in Germany, and adds Hamburg-based software and consulting capabilities to Kainos' existing Frankfurt presence and capabilities.

 

Both acquisitions help Kainos to build and expand on its Workday offering, and to grow its presence in key markets. By acquiring both businesses, Kainos strengthens its capabilities to sell, deliver and support Adaptive Insights financial planning customer success across the UK and wider Europe.

 

The terms of the investments have not been disclosed.

 

Commenting on the acquisition Brendan Mooney, CEO, Kainos, said:

 

"I am delighted to welcome the Formulate and Implexa teams to Kainos. The quality and unique expertise of the teams, paired with their complementary values, were integral in our decision to make these acquisitions.

 

We continue to see growing demand from organisations across the UK and Europe in modernising employee experience and financial management systems. By partnering with Workday, and as it continues to expand its products, we'll be able to enhance our value to customers."

 

For further information, please contact:

 

Kainos Group plc via FTI Consulting LLP

Brendan Mooney, Chief Executive Officer

Richard McCann, Chief Financial Officer

 

Investec Bank plc +44 20 7597 5970

Patrick Robb / Sebastian Lawrence

 

Canaccord Genuity +44 20 7523 4606

Simon Bridges

 

FTI Consulting LLP +44 20 3727 1000

Matt Dixon / Kwaku Aning / Leah Dudley

 

 

About Kainos

Kainos Group plc is a UK-headquartered provider of Digital Services and Digital Platforms.

 

The Group's Digital Services include full lifecycle development and support of customised Digital Services for government and commercial customers. Kainos is also the leading European partner for Workday, Inc. ('Workday'), responsible for implementing Workday's innovative Software-as-a-Service (SaaS) platform for enterprise and, now, government customers.

 

The Group's Digital Platforms comprise specialised digital platforms in the mobile healthcare and automated testing arenas. Smart is an automated testing platform for Workday customers; Evolve Electronic Medical Records ('EMR') is the market-leading product for the digitisation of patient notes in the Acute sector of the NHS.

 

Kainos has over 1,550 people across 12 offices in Europe and North America.

 

Kainos is listed on the London Stock Exchange (LSE: KNOS). For further information, please visit www.kainos.com 

 

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFSLFWAFUSEFF
Date   Source Headline
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSCapital Markets Event
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20257:00 amRNSTransaction in Own Shares
16th Oct 20257:00 amRNSTransaction in Own Shares
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 202511:08 amRNSDirector Declaration
14th Oct 20257:00 amRNSTransaction in Own Shares
13th Oct 20257:00 amRNSTransaction in Own Shares
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20253:04 pmRNSTotal Voting Rights
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSConfirmation of Board Changes
24th Sep 20257:00 amRNSTransaction in Own Shares
23rd Sep 20251:07 pmRNSResults of Annual General Meeting
23rd Sep 20257:00 amRNSTransaction in Own Shares
22nd Sep 20257:00 amRNSTransaction in Own Shares
19th Sep 20257:00 amRNS-RAcquisition in Canada of Davis Pierrynowski Ltd
19th Sep 20257:00 amRNSTransaction in Own Shares
18th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
16th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSTransaction in Own Shares
11th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
2nd Sep 202510:58 amRNSTotal Voting Rights
1st Sep 20257:00 amRNSTransaction in Own Shares
1st Sep 20257:00 amRNSTrading Statement
29th Aug 20257:00 amRNSTransaction in Own Shares
28th Aug 20257:00 amRNSTransaction in Own Shares
27th Aug 20257:00 amRNSTransaction in Own Shares
26th Aug 20257:00 amRNSTransaction in Own Shares
22nd Aug 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.